These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25327369)

  • 1. [Anticoagulant therapy with dabigatran in elderly patients ≥80 years of age with atrial fibrillation].
    Kono T; Ogimoto A; Aono J; Okura T; Shigematsu Y; Higaki J
    Nihon Ronen Igakkai Zasshi; 2014; 51(4):350-5. PubMed ID: 25327369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
    Fukaya H; Niwano S; Oikawa J; Nishinarita R; Horiguchi A; Nakamura H; Fujiishi T; Igarashi T; Ishizue N; Yoshizawa T; Satoh A; Kishihara J; Murakami M; Ako J
    J Cardiol; 2017 Mar; 69(3):591-595. PubMed ID: 27377855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA; Chee KH; Lo YL
    Int J Clin Pharm; 2016 Oct; 38(5):1182-90. PubMed ID: 27450507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
    JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran must be used carefully: literature review and recommendations for management of adverse events.
    Lin S; Wang Y; Zhang L; Guan W
    Drug Des Devel Ther; 2019; 13():1527-1533. PubMed ID: 31190734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran.
    Ji Q; Xu Q; Wang Z; Li X; Lv Q
    Eur J Clin Pharmacol; 2019 Mar; 75(3):321-328. PubMed ID: 30377709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
    Kawabata M; Yokoyama Y; Sasano T; Hachiya H; Tanaka Y; Yagishita A; Sugiyama K; Nakamura T; Suzuki M; Isobe M; Hirao K
    J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation.
    Ni L; Chen X; Liu M; Fan Y; Fu Z; Sun D; Zhao Z
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):359-364. PubMed ID: 33263436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
    Scott KA; Amirehsani KA
    J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dabigatran in a "real-life" population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry.
    Russo V; Bianchi V; Cavallaro C; Vecchione F; De Vivo S; Santangelo L; Sarubbi B; Calabrò P; Nigro G; D'Onofrio A
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3961-7. PubMed ID: 26531286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.
    Carley B; Griesbach S; Larson T; Krueger K
    Am J Cardiol; 2014 Feb; 113(4):650-4. PubMed ID: 24484861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.